BioNTech has lifted its revenue forecast for its blockbuster coronavirus vaccine to €17bn this year as demand for the jab continues to grow.
The German biotech, which launched the first Covid-19 vaccine in partnership with US pharmaceutical company Pfizer, said on Tuesday that revenues would be €1bn higher than previously forecast.
The company said it expected to sell 2.5bn doses of the vaccine this year, after singing contracts for another 300m doses in the past three months. By the end of the year, it would have produced 3bn jabs, it said.
您已阅读22%（545字），剩余78%（1936字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。